This content is only available within our institutional offering.
17 Dec 2019
ROCHE: The future looks increasingly bright in breast cancer | BUY - Top Picks | CHF350
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE: The future looks increasingly bright in breast cancer | BUY - Top Picks | CHF350
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
17 Dec 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
ROCHE - BUY - Top Picks | CHF350 (+16%)
The future looks increasingly bright in breast cancer
Roche is more offensive than defensive in BC now
TNBC is a second segment in which Roche is progressing
Roche might also go wider in HR+ BC
Meaningful upside to our numbers